STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
STAT
JANUARY 31, 2024
The announcement concerning the lower-dose starter product came as the company reported 2023 sales rose 36% and operating profit grew 44% at constant exchange rates, driven by massive sales of Wegovy and Ozempic, used to treat diabetes. Novo also projected double-digit growth in sales and operating profit for 2024.
Let's personalize your content